Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

695.28 -1.77 (-0.25%)
Streaming Delayed Price Updated: 11:41 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,154
Open 693.72
Bid (Size) 694.55 (40)
Ask (Size) 695.11 (120)
Prev. Close 697.05
Today's Range 686.36 - 698.63
52wk Range 510.06 - 934.62
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-17.2%
-17.2%
1 Month
-15.9%
-15.9%
3 Month
-18.2%
-18.2%
6 Month
-4.7%
-4.7%
1 Year
+14.8%
+14.8%

More News

Read More
News headline image
argenx announces Annual General Meeting of Shareholders on May 6, 2026
From argenx SE
Via GlobeNewswire
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Via Finterra
Topics Economy
News headline image
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
Via Stocktwits
News headline image
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
From argenx SE
Via GlobeNewswire
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at TD Cowen 46th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
From argenx SE
Via GlobeNewswire
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Via The Motley Fool
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Highlights 2026 Strategic Priorities
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Leadership Transition Marking Next Evolution of Growth
From argenx SE
Via GlobeNewswire
News headline image
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
Via PredictStreet
Topics Economy Intellectual Property
News headline image
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
From argenx SE
Via GlobeNewswire

Frequently Asked Questions

Is argenx SE - American Depositary Shares publicly traded?
Yes, argenx SE - American Depositary Shares is publicly traded.
What exchange does argenx SE - American Depositary Shares trade on?
argenx SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for argenx SE - American Depositary Shares?
The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market
What is the current price of argenx SE - American Depositary Shares?
The current price of argenx SE - American Depositary Shares is 695.28
When was argenx SE - American Depositary Shares last traded?
The last trade of argenx SE - American Depositary Shares was at 03/26/26 11:41 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.